Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Hanno, Wild"'
Publikováno v:
Angewandte Chemie. 125:2748-2751
Publikováno v:
Angewandte Chemie International Edition. 52:2684-2687
Publikováno v:
ChemInform. 47
Computational chemistry within the pharmaceutical industry has grown into a field that proactively contributes to many aspects of drug design, including target selection and lead identification and optimization. While methodological advancements have
Autor:
Christine Ellingsen, Dominik Mumberg, Lars Linden, Katrine Wickstroem, Urs B. Hagemann, Antje Margret Wengner, Jenny Karlsson, Hanno Wild, Alexander Kristian, Alan Cuthbertson, Karl Ziegelbauer, Roger M. Bjerke, Bertolt Kreft, Olav B. Ryan, Gerhard Siemeister
Publikováno v:
Cancer Research. 78:849-849
Targeted Thorium-227 Conjugates (TTCs) consist of the alpha particle emitter thorium-227 bound with high affinity by a 3,2-HOPO chelator covalently attached to a tumor-specific antibody. Thorium-227 has a half-life of 18.7 days and decays to the alph
Autor:
Anna Tafuri, Christoph Kneip, Liv-Ingrid Oedegaardstuen, Jenny Karlsson, Alan Cuthbertson, Christoph A. Schatz, Alexander Kristian, Hanno Wild, Dominik Mumberg, Karl Ziegelbauer, Christine Ellingsen, Katrine Wickstroem, Roger M. Bjerke, Urs B. Hagemann, Hartwig Hennekes, Anne Mobergslien, Joachim Schuhmacher
Publikováno v:
Cancer Research. 78:850-850
Targeted Thorium-227 Conjugates (TTCs) represent a new class of targeted alpha therapy. In this compound family a 3,2-HOPO chelator, which binds thorium-227 with high affinity, is covalently attached to an antibody. This enables the specific delivery
Autor:
Christine Ellingsen, Olav B. Ryan, Jenny Karlsson, Antje Margret Wengner, Dominik Mumberg, Hanno Wild, Anette Sommer, Katrine Wickstroem, Roger M. Bjerke, Urs B. Hagemann, Alan Cuthbertson, Alexander Kristian, Karl Ziegelbauer, Bertolt Kreft, Lars Linden
Publikováno v:
Cancer Research. 78:855-855
Targeted Thorium-227 Conjugates (TTCs) consist of the alpha emitter Thorium-227 (227Th) coupled, by a 3, 2-HOPO chelator, to a tumor specific antibody. The alpha particles release high energy over a short range (2- 10 cell diameters), resulting in a
Publikováno v:
Drug Discovery Today. 12:1025-1031
Ever-increasing research and development costs are putting constant pressure on the pharmaceutical industry to improve their efficiency. Efforts to increase the output of the research pipeline have yielded limited success. Traditionally, maximization
Publikováno v:
ChemMedChem. 10(12)
Computational chemistry within the pharmaceutical industry has grown into a field that proactively contributes to many aspects of drug design, including target selection and lead identification and optimization. While methodological advancements have
Autor:
Lars Linden, Hanno Wild, Jenny Karlsson, Anette Sommer, Thorsten Poethko, Roger M. Bjerke, Ellen Wang, Uta Wirnitzer, Urs B. Hagemann, Heidrun Ellinger-Ziegelbauer, Alexander Kristian, Alan Cuthbertson, Steffen Sandmann, Bertolt Kreft, Åsmund Larsen
Publikováno v:
Cancer Research. 77:5199-5199
FGFR2 is a transmembrane tyrosine kinase receptor, consisting of three extracellular N-terminal immunoglobulin-like domains which are involved in ligand-binding as well as in receptor dimerization. Ligand-independent activation of FGFR2 signaling eit
Publikováno v:
Angewandte Chemie. 123:7590-7592